nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR6—schizophrenia	0.364	0.453	CbGaD
Dihydroergotamine—HTR1B—schizophrenia	0.206	0.257	CbGaD
Dihydroergotamine—HTR1A—schizophrenia	0.163	0.203	CbGaD
Dihydroergotamine—ABCB1—schizophrenia	0.07	0.087	CbGaD
Dihydroergotamine—HTR1B—telencephalic ventricle—schizophrenia	0.00459	0.0852	CbGeAlD
Dihydroergotamine—HTR1D—telencephalic ventricle—schizophrenia	0.00444	0.0825	CbGeAlD
Dihydroergotamine—HTR1A—telencephalic ventricle—schizophrenia	0.0037	0.0688	CbGeAlD
Dihydroergotamine—HTR6—forebrain—schizophrenia	0.00199	0.0369	CbGeAlD
Dihydroergotamine—CYP3A4—urine—schizophrenia	0.00187	0.0346	CbGeAlD
Dihydroergotamine—HTR6—telencephalon—schizophrenia	0.00183	0.0339	CbGeAlD
Dihydroergotamine—HTR1A—blood plasma—schizophrenia	0.00177	0.0328	CbGeAlD
Dihydroergotamine—ADRA2A—blood plasma—schizophrenia	0.00124	0.023	CbGeAlD
Dihydroergotamine—HTR1B—forebrain—schizophrenia	0.0012	0.0222	CbGeAlD
Dihydroergotamine—HTR1D—forebrain—schizophrenia	0.00116	0.0215	CbGeAlD
Dihydroergotamine—HTR1B—telencephalon—schizophrenia	0.0011	0.0205	CbGeAlD
Dihydroergotamine—HTR6—nervous system—schizophrenia	0.00108	0.02	CbGeAlD
Dihydroergotamine—HTR2B—forebrain—schizophrenia	0.00108	0.02	CbGeAlD
Dihydroergotamine—HTR1D—telencephalon—schizophrenia	0.00107	0.0198	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—schizophrenia	0.00104	0.0193	CbGeAlD
Dihydroergotamine—HTR2B—telencephalon—schizophrenia	0.000992	0.0184	CbGeAlD
Dihydroergotamine—CYP3A4—blood plasma—schizophrenia	0.000974	0.0181	CbGeAlD
Dihydroergotamine—HTR1A—forebrain—schizophrenia	0.000967	0.018	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD1—schizophrenia	0.000963	0.128	CrCbGaD
Dihydroergotamine—HTR1A—telencephalon—schizophrenia	0.000889	0.0165	CbGeAlD
Dihydroergotamine—HTR6—brain—schizophrenia	0.000825	0.0153	CbGeAlD
Dihydroergotamine—HTR1B—midbrain—schizophrenia	0.000791	0.0147	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—schizophrenia	0.000766	0.0142	CbGeAlD
Dihydroergotamine—HTR2B—blood—schizophrenia	0.000722	0.0134	CbGeAlD
Dihydroergotamine—HTR1B—endocrine gland—schizophrenia	0.000695	0.0129	CbGeAlD
Dihydroergotamine—ABCB1—blood plasma—schizophrenia	0.000689	0.0128	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD2—schizophrenia	0.000679	0.0899	CrCbGaD
Dihydroergotamine—ADRA2A—forebrain—schizophrenia	0.000678	0.0126	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR6—schizophrenia	0.000671	0.0889	CrCbGaD
Dihydroergotamine—HTR1B—nervous system—schizophrenia	0.000651	0.0121	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—schizophrenia	0.000639	0.0119	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—schizophrenia	0.00063	0.0117	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—schizophrenia	0.000626	0.0116	CbGeAlD
Dihydroergotamine—ADRA2A—telencephalon—schizophrenia	0.000623	0.0116	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—schizophrenia	0.000606	0.0113	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—schizophrenia	0.000586	0.0109	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—schizophrenia	0.000564	0.0105	CbGeAlD
Dihydroergotamine—HTR1A—endocrine gland—schizophrenia	0.000561	0.0104	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—schizophrenia	0.000525	0.00975	CbGeAlD
Dihydroergotamine—ADRA2A—gonad—schizophrenia	0.00052	0.00966	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—schizophrenia	0.000505	0.00938	CbGeAlD
Dihydroergotamine—HTR1B—brain—schizophrenia	0.000497	0.00923	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—schizophrenia	0.000494	0.00917	CbGeAlD
Dihydroergotamine—HTR1D—brain—schizophrenia	0.000481	0.00894	CbGeAlD
Dihydroergotamine—ADRA2A—blood—schizophrenia	0.000453	0.00842	CbGeAlD
Dihydroergotamine—HTR2B—brain—schizophrenia	0.000448	0.00831	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—schizophrenia	0.000448	0.00831	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD4—schizophrenia	0.000428	0.0567	CrCbGaD
Dihydroergotamine—HTR1A—brain—schizophrenia	0.000401	0.00745	CbGeAlD
Dihydroergotamine—Ergotamine—HTR1B—schizophrenia	0.000394	0.0523	CrCbGaD
Dihydroergotamine—ADRA2A—endocrine gland—schizophrenia	0.000393	0.0073	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR7—schizophrenia	0.000393	0.052	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR1B—schizophrenia	0.00038	0.0504	CrCbGaD
Dihydroergotamine—ABCB1—forebrain—schizophrenia	0.000378	0.00701	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD3—schizophrenia	0.000369	0.0489	CrCbGaD
Dihydroergotamine—ADRA2A—nervous system—schizophrenia	0.000368	0.00683	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD1—schizophrenia	0.000362	0.048	CrCbGaD
Dihydroergotamine—CYP3A4—blood—schizophrenia	0.000357	0.00662	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—schizophrenia	0.000354	0.00658	CbGeAlD
Dihydroergotamine—ABCB1—telencephalon—schizophrenia	0.000347	0.00645	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—schizophrenia	0.000346	0.00643	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2C—schizophrenia	0.000321	0.0426	CrCbGaD
Dihydroergotamine—Ergotamine—HTR1A—schizophrenia	0.000312	0.0414	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2C—schizophrenia	0.00031	0.0411	CrCbGaD
Dihydroergotamine—CYP3A4—endocrine gland—schizophrenia	0.000309	0.00575	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR1A—schizophrenia	0.000301	0.0399	CrCbGaD
Dihydroergotamine—ABCB1—gonad—schizophrenia	0.00029	0.00538	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—schizophrenia	0.00029	0.00538	CbGeAlD
Dihydroergotamine—ADRA2A—brain—schizophrenia	0.000281	0.00522	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—schizophrenia	0.000279	0.00518	CbGeAlD
Dihydroergotamine—Ergotamine—DRD2—schizophrenia	0.000265	0.0351	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD2—schizophrenia	0.000255	0.0339	CrCbGaD
Dihydroergotamine—ABCB1—blood—schizophrenia	0.000253	0.00469	CbGeAlD
Dihydroergotamine—ABCB1—midbrain—schizophrenia	0.000249	0.00463	CbGeAlD
Dihydroergotamine—Ergotamine—CYP1A2—schizophrenia	0.000243	0.0321	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP1A2—schizophrenia	0.000234	0.031	CrCbGaD
Dihydroergotamine—ABCB1—endocrine gland—schizophrenia	0.000219	0.00407	CbGeAlD
Dihydroergotamine—ABCB1—nervous system—schizophrenia	0.000205	0.00381	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—schizophrenia	0.000205	0.0271	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2A—schizophrenia	0.000197	0.0262	CrCbGaD
Dihydroergotamine—ABCB1—central nervous system—schizophrenia	0.000197	0.00366	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—schizophrenia	0.000193	0.00358	CbGeAlD
Dihydroergotamine—ABCB1—brain—schizophrenia	0.000157	0.00291	CbGeAlD
Dihydroergotamine—Ergotamine—ABCB1—schizophrenia	0.000134	0.0177	CrCbGaD
Dihydroergotamine—Bromocriptine—ABCB1—schizophrenia	0.000129	0.0171	CrCbGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR7—schizophrenia	1.4e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD2—schizophrenia	1.4e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PLA2G4A—schizophrenia	1.4e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR7—schizophrenia	1.39e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD2—schizophrenia	1.39e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD4—schizophrenia	1.39e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—DPYD—schizophrenia	1.38e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL3RA—schizophrenia	1.38e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLCH2—schizophrenia	1.38e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR7—schizophrenia	1.37e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD2—schizophrenia	1.37e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGA—schizophrenia	1.37e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—schizophrenia	1.37e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—schizophrenia	1.36e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TLE1—schizophrenia	1.35e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRG3—schizophrenia	1.35e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRL—schizophrenia	1.34e-05	9.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GFAP—schizophrenia	1.33e-05	9.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NPY—schizophrenia	1.33e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ATP2A2—schizophrenia	1.33e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH4—schizophrenia	1.33e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRL—schizophrenia	1.33e-05	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CNR1—schizophrenia	1.32e-05	9.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GRM5—schizophrenia	1.32e-05	9.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRL—schizophrenia	1.3e-05	9.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NDST3—schizophrenia	1.29e-05	9.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR7—schizophrenia	1.29e-05	9.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD2—schizophrenia	1.29e-05	9.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR1B—schizophrenia	1.29e-05	9.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—OXT—schizophrenia	1.29e-05	9.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CACNA1C—schizophrenia	1.29e-05	9.54e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GCLM—schizophrenia	1.28e-05	9.52e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPH1—schizophrenia	1.28e-05	9.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TLE3—schizophrenia	1.28e-05	9.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3C2A—schizophrenia	1.25e-05	9.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—S100B—schizophrenia	1.25e-05	9.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—schizophrenia	1.24e-05	9.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—S100B—schizophrenia	1.24e-05	9.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ACSL6—schizophrenia	1.23e-05	9.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC27A5—schizophrenia	1.23e-05	9.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRL—schizophrenia	1.22e-05	9.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NPS—schizophrenia	1.22e-05	9.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—S100B—schizophrenia	1.21e-05	8.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCK—schizophrenia	1.21e-05	8.95e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PRKD1—schizophrenia	1.21e-05	8.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2C—schizophrenia	1.2e-05	8.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD1—schizophrenia	1.2e-05	8.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB4—schizophrenia	1.19e-05	8.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB4—schizophrenia	1.18e-05	8.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDE4B—schizophrenia	1.18e-05	8.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DAO—schizophrenia	1.17e-05	8.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NTRK2—schizophrenia	1.16e-05	8.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD3—schizophrenia	1.16e-05	8.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB4—schizophrenia	1.16e-05	8.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCKAR—schizophrenia	1.16e-05	8.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—S100B—schizophrenia	1.14e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD4—schizophrenia	1.12e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP2D6—schizophrenia	1.12e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SNAP25—schizophrenia	1.12e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PNP—schizophrenia	1.12e-05	8.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADORA2A—schizophrenia	1.12e-05	8.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PLA2G4A—schizophrenia	1.12e-05	8.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PLA2G4A—schizophrenia	1.11e-05	8.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PLA2G4A—schizophrenia	1.1e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—schizophrenia	1.1e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRG1—schizophrenia	1.1e-05	8.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRG1—schizophrenia	1.09e-05	8.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MEF2C—schizophrenia	1.09e-05	8.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PLA2G4A—schizophrenia	1.09e-05	8.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB4—schizophrenia	1.09e-05	8.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MEF2C—schizophrenia	1.08e-05	8.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGA—schizophrenia	1.08e-05	7.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—schizophrenia	1.07e-05	7.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CNR1—schizophrenia	1.07e-05	7.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRG1—schizophrenia	1.07e-05	7.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MEF2C—schizophrenia	1.06e-05	7.85e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—schizophrenia	1.06e-05	7.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—YWHAZ—schizophrenia	1.05e-05	7.81e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ATP2A2—schizophrenia	1.05e-05	7.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH4—schizophrenia	1.05e-05	7.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NPY—schizophrenia	1.05e-05	7.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD2—schizophrenia	1.05e-05	7.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR7—schizophrenia	1.05e-05	7.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—YWHAZ—schizophrenia	1.04e-05	7.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NDUFV2—schizophrenia	1.04e-05	7.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB3—schizophrenia	1.03e-05	7.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—YWHAZ—schizophrenia	1.02e-05	7.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PLA2G4A—schizophrenia	1.02e-05	7.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB3—schizophrenia	1.02e-05	7.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP1A2—schizophrenia	1.02e-05	7.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR1B—schizophrenia	1.01e-05	7.5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—OXT—schizophrenia	1.01e-05	7.5e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GAPDH—schizophrenia	1.01e-05	7.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRG1—schizophrenia	1e-05	7.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TH—schizophrenia	1e-05	7.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB3—schizophrenia	1e-05	7.42e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CLOCK—schizophrenia	9.97e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MEF2C—schizophrenia	9.94e-06	7.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—schizophrenia	9.91e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRL—schizophrenia	9.89e-06	7.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—schizophrenia	9.83e-06	7.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIP4K2A—schizophrenia	9.8e-06	7.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—schizophrenia	9.76e-06	7.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR1A—schizophrenia	9.73e-06	7.22e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPH2—schizophrenia	9.72e-06	7.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CACNB2—schizophrenia	9.72e-06	7.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—schizophrenia	9.72e-06	7.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—schizophrenia	9.63e-06	7.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—YWHAZ—schizophrenia	9.61e-06	7.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NPS—schizophrenia	9.58e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DPYD—schizophrenia	9.56e-06	7.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2C—schizophrenia	9.4e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD1—schizophrenia	9.4e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB3—schizophrenia	9.4e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—APOA1—schizophrenia	9.35e-06	6.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—S100B—schizophrenia	9.22e-06	6.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOE—schizophrenia	9.21e-06	6.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NTRK2—schizophrenia	9.14e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOE—schizophrenia	9.14e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOA1—schizophrenia	9.11e-06	6.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD3—schizophrenia	9.1e-06	6.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—schizophrenia	9.04e-06	6.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOA1—schizophrenia	9.04e-06	6.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—EP300—schizophrenia	9.01e-06	6.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOE—schizophrenia	8.95e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CACNA1C—schizophrenia	8.89e-06	6.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP26B1—schizophrenia	8.87e-06	6.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOA1—schizophrenia	8.85e-06	6.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD4—schizophrenia	8.83e-06	6.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB4—schizophrenia	8.81e-06	6.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ESR1—schizophrenia	8.79e-06	6.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ESR1—schizophrenia	8.73e-06	6.48e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3C2A—schizophrenia	8.66e-06	6.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ESR1—schizophrenia	8.55e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—COMT—schizophrenia	8.52e-06	6.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTP1—schizophrenia	8.48e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOA—schizophrenia	8.46e-06	6.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CNR1—schizophrenia	8.44e-06	6.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOE—schizophrenia	8.41e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOA1—schizophrenia	8.31e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PLA2G4A—schizophrenia	8.29e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD2—schizophrenia	8.23e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR7—schizophrenia	8.23e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—schizophrenia	8.21e-06	6.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRG1—schizophrenia	8.13e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MEF2C—schizophrenia	8.06e-06	5.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ESR1—schizophrenia	8.03e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ABCB1—schizophrenia	8.02e-06	5.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GSK3B—schizophrenia	7.98e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GSK3B—schizophrenia	7.92e-06	5.87e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPH1—schizophrenia	7.9e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCLM—schizophrenia	7.9e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—YWHAZ—schizophrenia	7.79e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PLA2G4A—schizophrenia	7.79e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTM1—schizophrenia	7.79e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRL—schizophrenia	7.77e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SNAP25—schizophrenia	7.77e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2D6—schizophrenia	7.77e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GSK3B—schizophrenia	7.75e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB3—schizophrenia	7.62e-06	5.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKD1—schizophrenia	7.43e-06	5.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—schizophrenia	7.33e-06	5.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GSK3B—schizophrenia	7.28e-06	5.4e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—S100B—schizophrenia	7.24e-06	5.37e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A2—schizophrenia	7.03e-06	5.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB4—schizophrenia	6.93e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TH—schizophrenia	6.93e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—schizophrenia	6.88e-06	5.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—schizophrenia	6.82e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOA1—schizophrenia	6.74e-06	5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLA2G4A—schizophrenia	6.51e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—schizophrenia	6.51e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—schizophrenia	6.45e-06	4.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—schizophrenia	6.41e-06	4.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRG1—schizophrenia	6.39e-06	4.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEF2C—schizophrenia	6.34e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—schizophrenia	6.34e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GAPDH—schizophrenia	6.2e-06	4.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CLOCK—schizophrenia	6.15e-06	4.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—YWHAZ—schizophrenia	6.12e-06	4.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB3—schizophrenia	5.99e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPH2—schizophrenia	5.99e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNB2—schizophrenia	5.99e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—schizophrenia	5.91e-06	4.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GSK3B—schizophrenia	5.9e-06	4.38e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—schizophrenia	5.89e-06	4.37e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—schizophrenia	5.89e-06	4.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—schizophrenia	5.87e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—schizophrenia	5.86e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOA—schizophrenia	5.85e-06	4.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—schizophrenia	5.76e-06	4.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—schizophrenia	5.75e-06	4.26e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNA1C—schizophrenia	5.48e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—schizophrenia	5.44e-06	4.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—schizophrenia	5.4e-06	4e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—schizophrenia	5.39e-06	4e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLA2G4A—schizophrenia	5.39e-06	4e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—schizophrenia	5.37e-06	3.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—schizophrenia	5.36e-06	3.98e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3C2A—schizophrenia	5.34e-06	3.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—schizophrenia	5.33e-06	3.95e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—schizophrenia	5.3e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—schizophrenia	5.25e-06	3.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—schizophrenia	5.22e-06	3.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—schizophrenia	5.21e-06	3.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—schizophrenia	5.12e-06	3.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—schizophrenia	5.1e-06	3.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—schizophrenia	4.9e-06	3.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—schizophrenia	4.79e-06	3.56e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2D6—schizophrenia	4.79e-06	3.55e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SNAP25—schizophrenia	4.79e-06	3.55e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—schizophrenia	4.76e-06	3.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GSK3B—schizophrenia	4.64e-06	3.44e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—schizophrenia	4.43e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—schizophrenia	4.38e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—schizophrenia	4.38e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A2—schizophrenia	4.33e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TH—schizophrenia	4.27e-06	3.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—schizophrenia	3.97e-06	2.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—schizophrenia	3.89e-06	2.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—schizophrenia	3.76e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—schizophrenia	3.73e-06	2.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—schizophrenia	3.65e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—schizophrenia	3.65e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—schizophrenia	3.63e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—schizophrenia	3.61e-06	2.68e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOA—schizophrenia	3.6e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—schizophrenia	3.44e-06	2.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—schizophrenia	3.43e-06	2.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—schizophrenia	3.42e-06	2.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G4A—schizophrenia	3.32e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—schizophrenia	3.32e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—schizophrenia	3.17e-06	2.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—schizophrenia	3.15e-06	2.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—schizophrenia	3.12e-06	2.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—schizophrenia	3.08e-06	2.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—schizophrenia	3.05e-06	2.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—schizophrenia	2.93e-06	2.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—schizophrenia	2.9e-06	2.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—schizophrenia	2.78e-06	2.06e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—schizophrenia	2.73e-06	2.03e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—schizophrenia	2.7e-06	2e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—schizophrenia	2.53e-06	1.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—schizophrenia	2.35e-06	1.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—schizophrenia	2.21e-06	1.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—schizophrenia	2.19e-06	1.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—schizophrenia	1.85e-06	1.37e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—schizophrenia	1.56e-06	1.15e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—schizophrenia	1.53e-06	1.13e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—schizophrenia	9.4e-07	6.98e-06	CbGpPWpGaD
